Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells

Keyphrases

• Protein Kinase 100%
• Cell Cycle Arrest 100%
• Prostate Cancer Cells 100%
• Protein Kinase Activity 100%
• Thiazolidine-2,4-dione 100%
• Leukemia Cells 100%
• Leukemic Cells 100%
• Benzylidene 100%
• Rapamycin 66%
• Cyclin-dependent Kinase 2 (CDK2) 66%
• Overexpressing 33%
• Mammalian Target of Rapamycin (mTOR) 33%
• Translational Repressor 33%
• 4E-BP1 33%
• Role in Cancer 33%
• Cancer Cells 33%
• Phosphorylation State 33%
• Cancer Progression 33%
• P27Kip1 33%
• Protein Kinase Inhibitors 33%
• IC50 Value 33%
• DU145 33%
• Cancer Development 33%
• Synergize 33%
• Cell Cycle Control 33%
• Tumor Malignancy 33%
• Prostate Tumor 33%
• Prostate Cancer Cell Lines 33%
• Cancer Types 33%
• Hematological Malignancies 33%
• MTOR Inhibitor 33%
• SCell 33%
• U937 Cells 33%
• Inhibitory Proteins 33%
• K562 Cells 33%
• Human Prostate Cancer Cells 33%
• PIM-1 33%
• Anticancer Target 33%
• Anti-apoptosis 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Protein Kinases 100%
• Prostate Cancer 100%
• Leukemia 100%
• Thiazolidine 100%
• Malignant Neoplasm 50%
• Rapamycin 50%
• Cyclin Dependent Kinase 2 50%
• Mammalian Target of Rapamycin 25%
• IC50 25%
• Anticarcinogen 25%
• Antiapoptotic 25%
• Prostate Tumor 25%
• Hematologic Malignancy 25%
• Mammalian Target of Rapamycin Inhibitor 25%
• Protein BAD 25%
• Peptides and Proteins 25%
• BH3 Protein 25%